These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35866147)

  • 1. The Real-World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study.
    Inose H; Ariga A; Motoyoshi T; Fukushima K; Tomizawa S; Kato T; Takahashi K; Yoshii T; Okawa A
    JBMR Plus; 2022 Jul; 6(7):e10637. PubMed ID: 35866147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
    Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
    Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRACP-5b/BAP Score After 3 Months of Treatment With Combined SERM/E2 Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia.
    Ota I; Ota Y; Ota K; Eda H; Ohta H
    JBMR Plus; 2022 Nov; 6(11):e10690. PubMed ID: 36398113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study.
    Mineta K; Nishisho T; Okada M; Kamada M; Sairyo K
    Bone; 2024 Sep; 186():117164. PubMed ID: 38871265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
    Kobayakawa T; Suzuki T; Nakano M; Saito M; Miyazaki A; Takahashi J; Nakamura Y
    Bone Rep; 2021 Jun; 14():101068. PubMed ID: 33981812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal responses to romosozumab after 12 months of denosumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Shi Y; Timoshanko J; Libanati C; Chines A; Oates MK
    JBMR Plus; 2021 Jul; 5(7):e10512. PubMed ID: 34258507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab.
    Hattori K; Kanayama Y
    Mod Rheumatol; 2024 Feb; ():. PubMed ID: 38300506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
    Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
    Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
    Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
    Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
    Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.
    Cosman F; Libanati C; Deignan C; Yu Z; Wang Z; Ferrari S; Beck Jensen JE; Peris P; Bertoldo F; Lespessailles E; Hesse E; Cummings SR
    JBMR Plus; 2021 Nov; 5(11):e10546. PubMed ID: 34761149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study.
    Sato M; Inaba M; Yamada S; Emoto M; Ohno Y; Tsujimoto Y
    J Bone Miner Metab; 2021 Nov; 39(6):1082-1090. PubMed ID: 34324082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Clin Nutr ESPEN; 2022 Apr; 48():267-274. PubMed ID: 35331501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study.
    Inage K; Orita S; Eguchi Y; Shiga Y; Koda M; Aoki Y; Kotani T; Akazawa T; Furuya T; Nakamura J; Takahashi H; Suzuki-Narita M; Maki S; Hagiwara S; Inoue M; Norimoto M; Kinoshita H; Sato T; Sato M; Enomoto K; Takaoka H; Mizuki N; Hozumi T; Tsuchiya R; Kim G; Otagiri T; Mukaihata T; Hishiya T; Ohtori S
    Yonsei Med J; 2021 Sep; 62(9):829-835. PubMed ID: 34427069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.
    Everts-Graber J; Wenger M; Oser S; Studer U; Steiner C; Ziswiler HR; Sromek K; Schmid G; Gahl B; Häuselmann H; Reichenbach S; Lehmann T
    Osteoporos Int; 2024 Jun; ():. PubMed ID: 38922397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
    Kasai H; Mori Y; Ose A; Shiraki M; Tanigawara Y
    J Clin Pharmacol; 2021 May; 61(5):606-613. PubMed ID: 33135182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.